Literature DB >> 24316910

Innovative therapies in Ewing Sarcoma.

Ana Teresa Amaral1, José Luis Ordóñez, Ana Pastora Otero-Motta, Daniel J García-Domínguez, María Victoria Sevillano, Enrique de Álava.   

Abstract

Ewing Sarcoma is a developmental tumor characterized by balanced chromosomal translocations and formation of new fusion genes, which are the main hallmark of this rare entity. Despite the vast knowledge regarding the molecular aspects of this rare malignancy obtained in the last few years, including the discovery of new therapeutic targets, many questions still remain open. In this review we focus on the research on targeted therapies in this malignancy, and discussed some bottlenecks related to this such as the possible role of pathologists, the availability of samples, the lack of appropriate animal models, and the resources needed to carry out preclinical and clinical research.

Entities:  

Mesh:

Year:  2014        PMID: 24316910     DOI: 10.1097/PAP.0000000000000003

Source DB:  PubMed          Journal:  Adv Anat Pathol        ISSN: 1072-4109            Impact factor:   3.875


  8 in total

1.  Vincristine, Ifosfamide, and Doxorubicin for Initial Treatment of Ewing Sarcoma in Adults.

Authors:  Michael J Wagner; Vancheswaran Gopalakrishnan; Vinod Ravi; J Andrew Livingston; Anthony P Conley; Dejka Araujo; Neeta Somaiah; Maria A Zarzour; Ravin Ratan; Wei-Lien Wang; Shreyaskumar R Patel; Alexander Lazar; Joseph A Ludwig; Robert S Benjamin
Journal:  Oncologist       Date:  2017-07-14

Review 2.  Bone- and cartilage-forming tumors and ewing sarcoma: an update with a gnathic emphasis.

Authors:  Brian D Stewart; John D Reith; Jacquelyn A Knapik; Angela C Chi
Journal:  Head Neck Pathol       Date:  2014-11-20

Review 3.  MicroRNA expression and its clinical implications in Ewing's sarcoma.

Authors:  Zheng Li; Xin Yu; Jianxiong Shen; William Ka Kei Wu; Matthew T V Chan
Journal:  Cell Prolif       Date:  2014-12-22       Impact factor: 6.831

4.  Multiple Active Compounds from Viscum album L. Synergistically Converge to Promote Apoptosis in Ewing Sarcoma.

Authors:  Monika Twardziok; Susann Kleinsimon; Jana Rolff; Sebastian Jäger; Angelika Eggert; Georg Seifert; Catharina I Delebinski
Journal:  PLoS One       Date:  2016-09-02       Impact factor: 3.240

5.  Transcriptomic and proteomic insight into the effects of a defined European mistletoe extract in Ewing sarcoma cells reveals cellular stress responses.

Authors:  M Twardziok; D Meierhofer; S Börno; B Timmermann; S Jäger; Sengül Boral; A Eggert; C I Delebinski; G Seifert
Journal:  BMC Complement Altern Med       Date:  2017-04-28       Impact factor: 3.659

6.  Sacral Ewing sarcoma with rib, lung, and multifocal skull metastases: A rare case report and review of treatments.

Authors:  Chen Ye; Wei Wei; Xuebin Tang; Feng Li; Baoquan Xin; Qianqian Chen; Haifeng Wei; Shaohui He; Jianru Xiao
Journal:  Front Oncol       Date:  2022-09-08       Impact factor: 5.738

7.  Trk inhibition reduces cell proliferation and potentiates the effects of chemotherapeutic agents in Ewing sarcoma.

Authors:  Tiago Elias Heinen; Rafael Pereira Dos Santos; Amanda da Rocha; Michel Pinheiro Dos Santos; Patrícia Luciana da Costa Lopez; Marco Aurélio Silva Filho; Bárbara Kunzler Souza; Luís Fernando da Rosa Rivero; Ricardo Gehrke Becker; Lauro José Gregianin; Algemir Lunardi Brunetto; André Tesainer Brunetto; Caroline Brunetto de Farias; Rafael Roesler
Journal:  Oncotarget       Date:  2016-06-07

8.  A seven-lncRNA signature for predicting Ewing's sarcoma.

Authors:  Zhihui Chen; Xinyu Wang; Guozhu Wang; Bin Xiao; Zhe Ma; Hongliang Huo; Weiwei Li
Journal:  PeerJ       Date:  2021-06-17       Impact factor: 2.984

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.